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ADH1B*2 is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, 
Independent of Alcohol Consumption
ADH1B rs1229984 (His48, ADH1B*2) associates with faster alcohol metabolism
1153 non-Hispanic whites with biopsy-proven NAFLD from NASH CRN 
ADH1B*2 associates with less NAFLD severity
Odds ratio (95% CI) P value
Definite NASH 0.50 (0.31-0.79) .003
NAS ≥4 0.48 (0.30-0.75) .001
Global fibrosis 0.69 (0.47-0.99) .050
Ballooning 0.53 (0.35-0.80) .001
MAC confers strongest protection against NASH among ADH1B*2 carriers
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Abstract:  
Background & Aims: Alcohol dehydrogenase 1B (ADH1B) is involved in alcohol metabolism. 
The allele A (ADH1B*2) of rs1229984: A>G variant in ADH1B is associated a higher alcohol 
metabolizing activity, compared to the ancestral allele G (ADH1B*1). Moderate alcohol 
consumption is associated with reduced severity of nonalcoholic fatty liver disease (NAFLD), 
based on histologic analysis, compared with no alcohol consumption. However, it is unclear 
whether ADH1B*2 modifies the relationship between moderate alcohol consumption and 
severity of NAFLD. We examined the association between ADH1B*2 and moderate alcohol 
consumption and histologic severity of NAFLD. 
Methods: We collected data from 1557 multi-ethnic adult patients with biopsy-proven NAFLD 
enrolled into 4 different studies conducted by the NASH Clinical Research Network. Histories of 
alcohol consumption were obtained from answers to standardized questionnaires. Liver biopsies 
were analyzed by histology and scored centrally according to the NASH CRN criteria. We 
performed covariate adjusted logistic regressions to identify associations between histologic 
features of NAFLD severity and moderate alcohol consumption and/or ADH1B*2.  
Results: A higher proportion of Asians/Pacific Islanders/Hawaiians carried the ADH1B*2 allele 
(86%) than other racial groups (4%–13%). However, the study population comprised mostly 
non-Hispanic whites (1153 patients, 74%), so the primary analysis focused on this group. Among 
them, 433 were moderate drinkers and 90 were ADH1B*2 carriers. After we adjusted for 
confounders, including alcohol consumption status, ADH1B*2 was associated with lower 
frequency of steatohepatitis (odds ratio [OR], 0.52; P<.01) or fibrosis (odds ratio, 0.69; P=.050) 
compared with ADH1B*1. Moderate alcohol consumption (g/day) reduced the severity of 
NAFLD in patients with ADH1B*1 or ADH1B*2. However, ADH1B*2, compared to ADH1B*1, 
was associated with a reduced risk of definite NASH (ADH1B*2 OR, 0.80; P<.01 vs ADH1B*1 
OR, 0.96; P=.036) and a reduced risk of an NAFLD activity score of 4 or higher (ADH1B*2 OR, 
0.83; P=.012 vs ADH1B*1 OR, 0.96; P=.048) (P<.01 for the difference in the effect of moderate 
alcohol consumption between alleles). The relationship between body mass index and NAFLD 
severity was significantly modified by ADH1B*2, even after we controlled for alcohol 
consumption.  
Conclusions: ADH1B*2 reduces the risk of NASH and fibrosis in adults with NAFLD 
regardless of alcohol consumption status. ADH1B*2 might modify the association between high 
body mass index and NAFLD severity. 
KEY WORDS: progression, risk factor, outcome, histology 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of 
chronic liver disease (CLD), affecting up to one third of American adults.1 By definition, a 
diagnosis of NAFLD requires the exclusion of significant alcohol consumption, which means > 7 
and > 14 standard drinks per week for women and men, respectively.2 It is worth to mention that 
up to 40% of patients with NAFLD report lifetime history of moderate alcohol consumption 
(MAC).3 The effect of MAC in patients with NAFLD remains controversial, with some cross-
sectional studies reporting that a MAC is associated with less severity in NAFLD and fibrosis.3-5 
Over the past decade, several longitudinal studies have shown that MAC lowers the risk of type 
2 diabetes mellitus (T2DM), hypertension, cardiovascular events, and these benefits may be 
partly explained by increased insulin sensitivity and high-density lipoprotein (HDL) levels as 
well as favorable effects on homeostatic factors and inflammatory pathways.6-8       
Alcohol dehydrogenase (ADH) enzymes are key regulators of alcohol metabolism. 
Polymorphisms in the genes encoding these enzymes result in the production of enzymes with 
different kinetic properties and different alcohol oxidizing capacities.9 One of the most studied 
single-nucleotide polymorphism in the ADH1B (Alcohol Dehydrogenase 1B (class I), Beta 
Polypeptide) gene is rs1229984, a G to A base transition in exon 3 leading to the substitution of 
arginine (Arg48, ADH1B*1) to histidine (His48, ADH1B*2) at position 48. ADH1B*2 allele 
encodes for an enzyme with approximately 80-fold higher turnover rate and 40 times more 
activity in producing acetaldehyde than ADH1B Arg48.9 Acetaldehyde buildup in the blood is 
associated with many unpleasant reactions following the consumption of alcohol, thus 
individuals with ADH1B*2 allele may refrain from drinking large quantities of alcoholic 
beverages and, therefore, may be protected against alcohol use disorders.10 However, whether 
this unpleasant reaction to alcohol in ADH1B*2 carriers results in a reluctance to drink alcohol 
after light or moderate alcohol intake is unclear. To address this question, a recent cross-sectional 
study assessed the effect of ADH1B*2 allele on the amount of alcohol consumption as well as its 
association with liver histology severity among patients with biopsy confirmed NAFLD.11 By 
using a Mendelian randomization analysis, authors found that carriers of the ADH1B*2 allele not 
only had lower consumption of alcohol but also decreased scores of histological steatosis, lobular 
inflammation and NAFLD activity score. The authors of the study suggest that the effect of 
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ADH1B*2 allele on the liver histology may be mediated exclusively by the amount of alcohol 
consumed and not by any other biological effect.  
The above-mentioned findings provided us the rationale to explore the relationship 
between MAC, the presence of ADH1B*2 allele and the liver histology severity in a large cohort 
of patients with biopsy-proven NAFLD. Thus, our study is aimed to determine the impact of 
ADH1B alleles on the current or lifetime average of alcohol intake, and to identify potential 
effects of current history of MAC or ADH1B alleles on histological severity of NAFLD. 
Additionally, we tested interactions effects between MAC and ADH1B rs1229984, and its 
potential effects on NAFLD histological phenotypes.  
METHODS 
Study design 
This is a cross-sectional study of prospectively evaluated adult patients with biopsy-
proven NAFLD who were enrolled into various studies conducted by the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK)-sponsored Nonalcoholic Steatohepatitis 
Clinical Research Network (NASH CRN). The present analysis includes patients enrolled into 
NAFLD Adult Database 1 (enrolling patients between 2004-2009), PIVENS (NCT00063622), 
FLINT (NCT01265498) and NAFLD Adult Database 2 (NCT01030484) (enrolling patients 
between 2009-2019), which is an extension of the NAFLD Adult Database 1 and uses the same 
patient’s selection criteria.12 13  
Briefly, individuals 18 years or older with a histological diagnosis of NAFLD were 
recruited at nine U.S. medical centers. Exclusion criteria included clinical or histological 
evidence of alcoholic liver disease or alcohol consumption of >7 and >14 standard drinks per 
week for women and men, respectively in the 2 years prior to screening, other causes of CLD, 
history of total parenteral nutrition, biliopancreatic diversion or bariatric surgery, short bowel 
syndrome, suspected or confirmed hepatocellular carcinoma and positivity for HIV. For the 
purpose of enrollment into this observational study, the diagnosis of NAFLD was based on the 
histological diagnosis of NAFLD or cryptogenic cirrhosis or on imaging studies. The current 
analysis included participants who had collected information on central review of liver histology, 
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alcohol consumption questionnaires (AUDIT and lifetime drinking history),14, 15 ADH1B 
rs1229984 and PNPLA3 rs738409 genotyping through July 2019.  
Participants with lifetime history of binge (4 or 5 standard drinks for women and men in a 
typical drinking day) or heavy drinking (>7 and >14 standard drinks per week for women and 
men, respectively) as captured by Lifetime Drinking History (LDH) questionnaire were 
excluded.15  
All patients gave written informed consent. The medical ethical committees of the 
participating hospitals approved the study protocol.  
Assessment of liver histology 
For this study, only patients with liver biopsy data available within 6 months of the clinic 
data were included. The NASH CRN Pathology committee, constituted by a group of nine 
hepatopathologists who were unaware to all clinical and identifying data, reviewed all liver 
biopsies centrally. The histological diagnosis was based on consensus recognition of a classical 
zone 3 distribution of histological features including steatosis, lobular inflammation and 
ballooning hepatocyte, thus, diagnosis of NASH was established independent of the NAS scoring 
and classified as definite steatohepatitis, simple steatosis or suspicious for NASH (“borderline” 
NASH) based upon central pathology reading.16 For the purposes of this analysis, the presence of 
definite steatohepatitis, an NAFLD activity score of 4 of higher including at least 1 point for 
each individual component (steatosis=1, lobular inflammation=1 and ballooning=1) and 
advanced stages of fibrosis (bridging fibrosis or cirrhosis) were considered as measures of 
NAFLD severity. Each of these three histological categories seem to be associated with higher 
risks of progression to cirrhosis or NAFLD-related complications. Other study outcomes 
included the analysis of ordered categorical histological variables such as steatosis (<5%, 5–
33%, 34–66%, >66%), lobular inflammation (<2, 2–4, and >4 x 20 field), portal inflammation 
(none, mild, more than mild), ballooning hepatocellular degeneration (none, few, many), 
Mallory-Denk bodies (absent or rare, many), and fibrosis stages (0= no fibrosis; 1= mild/zone 3 
perisinusoidal fibrosis or moderate/zone 3 perisinusoidal fibrosis or portal/periportal only 
fibrosis; 2= zone 3 perisinusoidal and periportal fibrosis; 3= bridging fibrosis; 4=cirrhosis).2, 16, 17  
Alcohol consumption assessment 
Vilar-Gomez and colleagues (8) 
At study enrollment, a comprehensive history of alcohol consumption was obtained via 
AUDIT 14 and LDH 15 questionnaires in all patients. For our primary analysis, the exposure of 
alcohol intake was classified as follows: (1) moderate drinkers defined as having a history of 
MAC (≤ 7 and ≤ 14 standard drinks per week for women and men, respectively) during the 2 
years before study enrollment, and (2) non-drinkers defined as absence of any amount of alcohol 
intake during the 2 years preceding study entry. The last group included either those who did not 
report drinking alcohol at any time or those who had a previous history of MAC but became 
abstainers in the last 2 years preceding the liver biopsy. In order to quantify the daily intake of 
alcohol (g/day), we considered that approximately 14 g of alcohol equals one 'drink' unit. One 
unit equals 1 ounce of distilled spirits, one 12-oz beer, or one 4-oz glass of wine. More details on 
alcohol consumption can be found in the supplemental material.      
ADH1B rs1229984 and PNPLA3 rs738409 genotyping 
DNA samples were received from the CRN consortium at a minimum concentration of 50 
ng/µl per sample. ADH1B (rs1229984) (NM_000668.6:c143 A>G) is a missense coding variant; 
this single nucleotide polymorphism results in an arginine [CGC] to histidine [CAC] 
substitution. SNP (rs738409) in PNPLA3 gene is a missense coding variant as well 
(NM_025225.3: c.444C>G), and results in an Ile [ATC] to Met [ATG] substitution. For quality 
control of ADH1B genotyping, duplicated analyses were conducted in 96 randomly selected 
samples. Genotyping results were identical between duplicated samples. More detailed 
information can be found in supplemental material.   
Clinical and laboratory parameters assessment 
The following parameters were systematically assessed in all participants at the enrollment 
visit: demographic factors including age, sex, race, and ethnicity; anthropometrics including 
body mass index (BMI [kg/m2]) and waist circumference; the presence of comorbidities 
including arterial hypertension and T2DM; laboratory tests including aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) levels, a lipid panel comprising total cholesterol, 
HDL, low-density lipoprotein (LDL) cholesterol and triglycerides, and finally hemoglobin A1c 
(HbA1c), fasting glucose and insulin as well as the homeostasis model assessment of insulin 
resistance (HOMA-IR) index. 
Statistical analysis 
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Data are expressed as mean (SD), and number and percent. Chi-squared or Mantel-
Haenszel trend tests were used for binary categorical variables. T test or Wilcoxon rank-sum test 
were used for continuous variables (e.g., to assess the association between continuous baseline 
characteristics and ADH1B alleles). The dose response association between daily alcohol 
consumption (0, 0-6.9, 7-13.9, and 14-28 grams per day) or ADH1B alleles with histological 
features including 2 or more ordinal categories was tested using the Cochran-Armitage trend test.  
Because of the low minor allele frequency for ADH1B*2 (A allele) and the small number 
of subjects homozygous for the minor allele (0.6%), the GA heterozygous and AA homozygous 
individuals were combined into a single group for analysis and compared with GG (ADH1B*1 
allele) homozygous individuals. An exact test was used to examine Hardy-Weinberg Equilibrium 
(HWE). Since PNPLA3 and ADH1B are in different chromosomes, there is no need for linkage 
disequilibrium analysis. 
Logistic regression models were used to estimate the odds ratios (ORs) and corresponding 
95% confidence intervals (CIs). To assess the association between history of MAC (drinkers vs 
non-drinkers) and ADH1B alleles (ADH1B*1 vs ADH1B*2) and ordinal histological categorical 
variables including three or more groups, multiple ordered logistic regression models were 
performed. Binary logistic regression analyses were performed for testing association between 
binary histological variables (e.g., definite NASH vs no NASH) and history of MAC and 
ADH1B alleles. Although the independence of the effect of ADH1B alleles on liver histology 
severity was explored through covariate-adjusted logistic analysis, we also sought to illustrate 
the effect of ADH1B alleles on histological outcomes among drinkers and non-drinkers, 
separately. 
Multivariable adjusting models included age, gender, race (Non-Hispanic whites, 
Hispanics, Blacks, Asians/Pacific Islanders/Hawaiians and others), BMI, T2DM and PNPLA3 
rs738409 genotypes. Margin plots with its predicted probabilities for the presence of definite 
NASH or an NAS ≥4 were displayed to visualize the main effect of a one unit change in alcohol 
consumption (g/day) or BMI (kg/m2) for each ADH1B allele and the impact on histological 
outcomes.18 Measures of interaction on a multiplicative or an additive scale were used to assess 
interactions between alcohol consumption [yes/no] or BMI (≤37 or >37 kg/m2) and ADH1B 
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alleles.19 Interaction on an additive scale was quantified using the relative excess risk due to 
interaction (RERI) and the proportion attributable to interaction (AP).19 No missing observations 
were found for those variables included in our main statistical analyses (liver histology scores, 
ADH1B alleles and PNPLA3 rs738409 genotypes, alcohol consumption history, BMI, age, 
gender and T2DM).      
A 2-tailed p-value <.05 was considered significant. Statistical analyses were carried out 
with the Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC. 
RESULTS 
A total of 1697 patients were assessed for eligibility, and 1557 were included for baseline data 
and outcome analysis. Based on lifetime drinking history, 39 and 131 binge and heavy drinkers 
were excluded (Figure 1). The frequency of ADH1B*2 carriage varied widely across race/ethnic 
categories, being high in Asians/Pacific Islanders/Hawaiians (86%) and low in non-Hispanic 
whites (8%), Hispanics (14%) and Blacks (4%). The Hardy-Weinberg test confirmed the 
independent segregation of the individual ADH1B alleles (p =.08 for Asians/Pacific 
Islanders/Hawaiians and p =.06 for non-Hispanic whites). The supplemental Table 1 shows 
baseline patients’ characteristics in the entire multi-ethnic cohort (n=1557). In order to reduce the 
effect of race/ethnicity on ADH1B allelic frequencies and its potential influence on NAFLD 
severity, our primary analysis focuses on non-Hispanic whites who comprise 74% (n=1153) of 
the whole study population.      
Baseline characteristics among non-Hispanic whites 
According to the most recent history of MAC (during the 2 years preceding the study 
enrollment), the cohort included 720 non-drinkers and 433 moderate drinkers (Figure 1). The 
mean age is 50.73 ± 11.46 years, and most patients are females (727, 63%), obese (mean BMI, 
34.87 ± 6.41) and have hypertension (685, 59%). T2DM is observed in 408 (35%) patients. 
Three hundred and forty-four (30%) have advanced fibrosis (stages of fibrosis ≥3), 689 (60%) 
and 690 (60%) have definite NASH or an NAS ≥4 on liver histology reports.  
Baseline characteristics according to ADH1B alleles (ADH1B*1 vs ADH1B*2) 
  Vilar-Gomez and colleagues (11) 
 
Table 1 displays demographical, clinical and laboratory characteristics according to 
ADH1B alleles. As compared to ADH1B*1, ADH1B*2 carriers are more likely to be male and 
have higher insulin sensitivity and triglycerides levels. The proportion of patients with lifetime or 
current history of MAC is not different between both alleles. The daily average of current 
alcohol consumption (g/day) is 1.68 ± 3.63 in ADH1B*2 as compared with 1.49 ± 3.49 in 
ADH1B*1, P=.630.  
Association between alcohol consumption and liver histology severity 
Table 2 shows the frequency and adjusted odds ratios for each histological feature based 
on the history of MAC. The prevalence of definite NASH, an NAS ≥4 and advanced fibrosis 
(stages of fibrosis ≥3) is significantly lower among drinkers compared with non-drinkers (52% 
vs 64%, 54% vs 63%, and 25% vs 33% respectively). Compared with non-drinkers, MAC is 
associated with a significantly decreased risk of severity of steatohepatitis (Adj. OR: 0.73 [95% 
CI: 0.57-0.94]), global fibrosis (Adj. OR: 0.68 [95% CI: 0.55-0.85]), definite steatohepatitis 
(Adj. OR: 0.70 [95% CI: 0.54-0.91]) and an NAS ≥4 (Adj. OR: 0.77 [95% CI: 0.60-0.99]) after 
adjustment by potential confounders, including ADH1B alleles, age, gender, BMI, T2DM and 
PNPLA3 rs738409 genotypes. In further sensitivity analysis including the entire multi-ethnic 
cohort and adjusting by same variables plus race/ethnicities, the association of MAC with 
steatohepatitis and fibrosis remains statistically significant (supplemental Table 2). 
A strong dose-dependent association is observed among daily MAC (g/day) and several 
histology features of NAFLD (Table 3). A higher amount of cumulative dose of alcohol 
consumed (between 1-28 g/day) is found to be associated with a lesser severity of ballooning 
hepatocyte degeneration, portal inflammation, Mallory-Denk bodies, steatohepatitis and fibrosis; 
these associations also remain significant when analyzed in the multi-ethnic cohort. 
(supplemental Tables 2 and 3).          
Association between ADH1B alleles and liver histology severity 
The presence of ADH1B*2 allele is associated with lower severity in lobular 
inflammation, hepatocyte ballooning degeneration, fibrosis, and steatohepatitis including definite 
NASH and an NAS ≥4 as compared with ADH1B*1 (Table 2). On the multivariable adjusted 
analyses, ADH1B*2 carriers show reduced risk of severity of steatohepatitis (Adj. OR: 0.52 
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[95% CI: 0.34-0.78]) and fibrosis (Adj. OR: 0.69 [95% CI: 0.47-0.99]) as well as definite NASH 
(Adj. OR: 0.50 [95% CI: 0.31-0.79]) and an NAS ≥4 (Adj. OR: 0.48 [95% CI: 0.30-0.75]); these 
associations remain significant even after adjustments by alcohol consumption, gender, BMI, 
T2DM and PNPLA3 rs738409 genotypes as shown in Table 2 and supplemental Tables 4 and 
5. Similar associations were found in the multi-ethnic cohort as compared with the non-Hispanic
white population, with the exception of lobular inflammation (supplemental Table 2). 
Finally, no significant interactions were seen between PNPLA3 rs738409 SNP and either 
ADH1B*2 or MAC (Supplemental Tables 4 and 5).   
Multiplicative and additive interaction effects between ADH1B alleles, MAC, and its impact on 
NAFLD severity 
Figure 2 displays multiplicative effects between ADH1B alleles and alcohol intake (grams 
per day) and their impacts on risk of definite NASH (Panel A) and an NAS ≥4 (Panel B). We 
observe an inverse dose-dependent relationship between the amount of alcohol intake and risk of 
definite NASH or an NAS ≥4. Although alcohol consumption seems to reduce risk of NASH in 
patients with ADH1B*1 or ADH1B*2, adjusted odds of having definite NASH or an NAS ≥4 for 
each gram of alcohol consumed are significantly lower in carriers of ADH1B*2 (Adj. OR for 
definite NASH: 0.80 [95 CI: 0.68-0.94] and Adj. OR for an NAS ≥4: 0.83 [95% CI: 0.72-0.96]) 
than ADH1B*1 (Adj. OR for definite NASH: 0.96 [95% CI: 0.93-0.99] and Adj. OR for an NAS 
≥4: 0.96 [95% CI: 0.93-0.99]), P<.001 for difference in the effect of alcohol intake on definite 
NASH or an NAS ≥4 between alleles. Supplemental Tables 6 and 7 illustrate P values and 
confidence intervals for differences in predicted probabilities of having definite NASH and an 
NAS ≥4 according to both ADH1B alleles in each category of alcohol consumed.  
We further explored multiplicative and additive interaction effects between MAC 
considered as a categorical variable (yes/no) and ADH1B alleles, and their impacts on NASH 
severity. MAC associates with lower risk for definite NASH or an NAS ≥4 in patients carrying 
ADH1B*2 (Adj. ORs of 0.22 [95% CI: 0.10-0.49] or 0.28 [95% CI: 0.13-0.60], respectively) 
compared with ADH1B*1 (Adj ORs of 0.71 [95% CI: 0.54-0.92] or 0.59 [95% CI: 0.34-1.05], 
respectively), P<.001 for difference in the effect of MAC on definite NASH or an NAS ≥4 
between alleles. ORs of 0.22 and 0.28 for the ADH1B*2 x MAC multiplicative term mean that 
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the combined effect of ADH1B*2 and MAC is 0.22 and 0.28 times the product of the individual 
effects of ADH1B*2 and MAC. Further analysis exploring interactions on an additive scale show 
a relative excess risk due to interaction (RERI) of -0.132 (95% CI: -0.589 to -0.089) and -0.153 
(95% CI: -0.611 to -0.093) for the ADH1B*2 x MAC interaction term and its risk on definite 
NASH or an NAS ≥4, respectively. These RERI mean that the risk of having definite NASH or 
an NAS ≥4 in ADH1B*2 carriers who drink moderate alcohol is 0.132 or 0.153 less than if there 
were no interaction between MAC and ADH1B*2. Supplemental Table 8 depicts results of 
ADH1B*2-by-MAC (yes/no) interactions on a multiplicative or an additive scale.  
 To confirm the previous findings, we sought to explore the effect of ADH1B*2 allele on 
the severity of NAFLD based on the history of MAC (yes/no), although the number of patients in 
each subgroup was too small for testing statistical significance on multivariable analysis. The 
direction and magnitude of the effect of ADH1B*2 was similar to that seen in the whole cohort 
for hepatocyte ballooning degeneration, definite NASH or an NAS ≥ 4 among drinkers and non-
drinkers. There was less clear relationship between ADH1B*2 and fibrosis, probably because of 
the small number of patients with ADH1B*2 in each group (Table 4). 
The association between ADH1B alleles and liver histology severity in drinkers and non-
drinkers remain significant and in general of similar magnitude in the multi-ethnic population 
than in non-Hispanic whites (upplemental Table 9).  
Multiplicative and additive interactions effects between ADH1B alleles and BMI and its impact 
on NAFLD severity 
The BMI average is significantly lower in moderate drinkers (34.18 ± 6.12) than non-
drinkers (35.29 ± 6.55), P=.005. Moderate drinkers carrying ADH1B*2 (32.93 ± 5.92) show 
lower mean BMI levels than those carrying ADH1B*1 (34.29 ± 6.3), P=.047 (supplemental 
Figure 1). Because of the relationship between alcohol consumption, BMI and ADH1B alleles, 
we sought to explore the impact of a two-way interaction term of ADH1B alleles-by-BMI 
(kg/m2) on predicted probabilities of definite NASH while controlling by alcohol consumption 
status, age and gender (Figure 3A). There is a positive association between BMI and risk of 
definite NASH, but interestingly the risk seems to be lower in ADH1B*2 carriers who have a 
BMI of ≤ 37 (see bolded P values in the supplemental Table 10) compared with ADH1B*1 
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carriers. We identify statistically significant interaction effects between ADH1B*2 and BMI 
categorized as ≤37 and >37 kg/m2 on probabilities of having definite NASH (P<.001) 
(Supplemental Table 11). An OR of 0.23 (95% CI: 0.12-0.43) for the ADH1B*2 x BMI 
multiplicative term mean that the combined effect of ADH1B*2 and BMI is 0.23 times the 
product of the individual effects of ADH1B*2 and BMI. A RERI of -0.282 (95% CI: -1.00 to -
0.037) means that the risk of having definite NASH in ADH1B*2 carriers who have BMI ≤ 37 is 
0.282 less than if there were no interaction between BMI and ADH1B*2.  
To confirm the previous findings, we sought to explore the association between ADH1B 
alleles and selected NAFLD features among patients with or without BMI ≤ or >37. To do so, 4 
groups ([1] BMI ≤37 with ADH1B*1; [2] BMI ≤37 with ADH1B*2; [3] BMI >37 with 
ADH1B*1; [4] BMI >37 with ADH1B*2) were created (Figures 3B, 3C and 3D). Among 
patients with BMI ≤ 37, the severity of NAFLD including categories of NASH (no 
steatohepatitis, and borderline and definite NASH) or NAFLD activity score (NAS <4 vs NAS 
≥4) and fibrosis (from stage 0 to 4) is significantly lower amongst patients carrying ADH1B*2 
than those carrying ADH1B*1. Among individuals with BMI >37, no difference is observed 
between ADH1B alleles. Interestingly, the proportion of patients with history of MAC is not 
different among the 4 groups: BMI ≤37 (ADH1B*2 [44%] vs ADH1B*1 [40%], P=.466) and 
BMI >37 (ADH1B*2 [28%] vs ADH1B*1 [32%], P=.621), so alcohol consumption status does 
not seem to impact the association between ADH1B alleles and BMI on NAFLD severity.      
DISCUSSION 
The present study examines the relationship between a coding variant in alcohol 
dehydrogenase 1B (rs1229984), MAC, and risk for steatohepatitis and fibrosis severity among 
individuals with biopsy-proven NAFLD. Our data reveal that individuals with ADH1B*2 have 
significantly decreased risk of several histological features of NAFLD including hepatocyte 
ballooning degeneration, lobular inflammation, steatohepatitis and global fibrosis, and this 
“protective” effect remains significant even after controlling by alcohol consumption status and 
other well-known confounding factors including age, gender, T2DM, BMI and PNPLA3 
rs738409 SNP. Our results also confirm that MAC reduces the severity of steatohepatitis in a 
dose-dependent manner in both ADH1B alleles, although greater benefits are observed in patients 
with the ADH1B*2 allele.  
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A recent Mendelian Randomization study examined the effect of ADH1B*2 allele on the 
amount of alcohol consumption as well as its association with liver histology severity among 
NAFLD patients. Authors reported that carriers of the ADH1B*2 allele not only have lower 
consumption of alcohol but also decreased scores of histological steatosis, lobular inflammation 
and NAFLD activity score. They assumed that the effect of ADH1B*2 on the liver histology is 
mediated exclusively by the amount of alcohol consumed and not by any other biological 
effect.11 Surprisingly, we do not find a significant effect of ADH1B*2 on different parameters 
related with alcohol consumption, and this finding could partly be explained by the low overall 
consumption observed in our cohort. To date, most of studies confirming protective effects of 
ADH1B*2 on alcohol consumption are primarily focused on populations with heavier drinking 
patterns who are at higher risk of developing a tolerance and dependence to alcohol. Some 
studies exploring association between ADH1B*2 and alcohol intake in populations with more 
heterogeneous patterns of drinking failed to detect protective effects on alcoholism, and 
hypothesized that it is likely due to low quantities of alcohol intake.20, 21  
Epidemiological studies have shown that light or moderate alcohol consumption, among 
male and female drinkers, are negatively associated with adiposity indicators (BMI, waist 
circumference and waist-to-hip ratio) compared to heavy drinking or abstention.22 Whilst many 
factors such as gender, type, frequency and amount of alcohol consumed, physical activity, 
dietary habits, etc. may confound the alcohol-related effects on BMI, genetic aspects can also 
play a role in the predisposition of individuals to gain weight as a result of alcohol intake. Recent 
reports show that ADH1B polymorphisms affect susceptibility to alcoholism and may affect body 
weight via gene-associated differences in fuel utilization.23, 24 ADH1B*2 allele is found to be a 
strong determinant of body weight in alcoholics.24 The more rapid ethanol elimination associated 
with the ADH1B*2 allele may result in less efficient utilization of ethanol as an energy source, 
which may result in lower weight gain compared with ADH1B*1 carrier. Consistent with 
previous findings, our study shows a differential effect of ADH1B*2 allele on body weight based 
on alcohol consumption status. Among patients with history of MAC, body weight is 
significantly lower in carriers of ADH1B*2 compared with ADH1B*1, however no effect is seen 
among non-drinkers.   
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Our ADH1B-by-BMI interaction analysis also show a genetic independence between the 
two ADH1B alleles and its association with NAFLD severity. Although a positive dose-
dependent association exists between body weight and NAFLD severity, the risk of having 
definite NASH seems to be attenuated among individuals with ADH1B*2 allele as compared 
with ADH1B*1; however, this “protective” effect disappears in presence of BMI higher than 37 
kg/m2. Although the possible biological mechanisms underlying this finding are not entirely 
clear, it is increasingly accepted the relationship between increased levels of nondietary ethanol 
(derived from bacteria)25 in obese individuals26, 27 and the severity of NAFLD.27, 28 Fasting 
plasma ethanol levels are strongly associated with body weight; and this association seems to be 
independent of dietary pattern or physical activity.29, 30  
In addition to increased obesity-related production of ethanol, other hypotheses suggest 
that modifications in insulin signaling followed by decreased ADH activity in the liver or 
adipose tissue could be responsible for an impaired ethanol metabolism.31, 32 In this regard, 
earlier studies conducted in rats suggest that activity of ADH is significantly reduced by high 
carbohydrate fat-free diet feeding compared with a normal chow diet. Furthermore in diabetic 
rats, ADH activity is found to be reduced by approximately 53% when compared with control 
animals.31 The overproduction of endogenous ethanol along with impairments in insulin 
signaling in obese and diabetic patients may alter ADH activity in the liver, subsequently leading 
to an impaired ethanol metabolism and elevated blood ethanol levels in patients with NAFLD. 
The increased production of microbiota-related ethanol may result in upregulation of activity of 
the enzyme cytochrome P450 2E1, which catalyzes the oxidation of ethanol, but produce free 
radicals favoring oxidative damage, mitochondrial dysfunction and liver inflammation.33 We 
hypothesized that individuals carrying the ADH1B*2 allele have an ADH1B2 allozyme that 
exhibits a higher activity for ethanol oxidation, and therefore higher alcohol elimination rates 
than those with wild-type ADH1B alloenzyme. Thus, ADH1B*2 carriers may, theoretically, be 
less vulnerable to the overproduction of endogenous or dietary alcohol, and therefore, exhibit 
less liver damage.34 However, the mechanism for this protective effect is uncertain and the effect 
of ADH1B*2 variant on the risk of NAFLD severity could be more complex. Because of the 
ADH1B2 allozyme exhibits a higher activity for ethanol oxidation, in presence of higher 
overproduction of endogenous alcohol in those with higher BMI or dietary alcohol, hepatic 
injury might result from high intrahepatic concentrations of acetaldehyde.35 This finding might 
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be a compatible explanation of the increased vulnerability to liver injury in carriers of ADH1B*2 
with higher BMI, although the relationship between BMI and ADH1B variants remains largely 
unknown and it warrants further investigation. 
The ADH1B expression varies across multiple human tissues (http://BioGPS.org), 
including the liver and adipose tissue, among others. A recent study including human abdominal 
subcutaneous adipose tissue of 75 Mexican Americans found a strong and inverse relationship 
between ADH1B expression with obesity-related traits and insulin resistance. These direct links 
of ADH1B expression with various anthropometric measures, including waist circumference 
indicate a strong association of ADH1B with central obesity and insulin resistance, and a possible 
link with multiple metabolic traits, including T2DM and NAFLD. Unfortunately, the 
contribution of ADH1B activity in adipocytes to whole body ethanol clearance is not fully 
understood. However, it has been suggested that, in obese individuals, the adipose tissue may 
significantly be involve in alcohol elimination, although this could vary depending on genetic 
and/or environmental factors.36 Therefore, down-regulation of ADH1B expression in the adipose 
tissue of obese individuals could potentially reduce the ethanol elimination and contribute to the 
worsening detrimental metabolic effects of increased adiposity.  
Finally, it has been suggested that ADHs may also be involved in other non-alcohol 
related molecular pathways including all-trans-retinol and its derivatives, and lipid peroxidation 
products 37, 38 which are known to be relevant to NAFLD pathophysiology. ADH are involved in 
the oxidation of retinol (ROL) to retinal (RAL), the first step in the biosynthesis of retinoic acid 
(RA).39 RA is an active metabolite of vitamin A which has been implicated in the regulation of 
lipid metabolism and hepatic steatosis, inflammation and fibrosis in animal and humans 
studies.40 Previous studies have suggested that ethanol is implicated in disruption of RA 
homeostasis; specifically it has the potential to inhibit ADH-mediated oxidation of retinol to 
retinal, the rate-limiting step in RA biosynthesis.41, 42 ROL is an important endogenous substrate 
for liver ADH, and its oxidation seems to be affected by genetic polymorphisms in ADH1B. In 
an elegant study, Chase, et al. showed that the ADH1B2 alloenzyme leads to greater ROL 
oxidation at different ethanol levels and, therefore, lesser impairment of the biogenesis of RA.43   
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We recognize several potential limitations of our study. First, the alcohol consumption 
was collected based on self-reported information, which may result in underestimates of the 
effects of individual SNPs due to alcohol consumption misclassification. Nonetheless, self-
reported measures of alcohol intake have been shown to correlate strongly with the genetic risk 
for alcohol use disorders.44 Second, a further limitation is our inability to examine the effect of 
ADH1B SNPs-by-alcohol intake associations on liver histology outcomes among Asians/Pacific 
Islanders/Hawaiians individuals. This was because the present study involves a relatively small 
number of Asians, Pacific Islanders and Hawaiians in whom the frequency of the wild-type 
ADH1B is lower. Thus, validations of our findings including more diversely ethnic populations 
are warranted. Unfortunately, the proportion of patients with ADH1B*2 allele in each subgroup 
is smaller (n=55 in non-drinkers and n=35 in drinkers). We assumed that the case numbers are 
too limited to run analysis in these subpopulations while adjusting by relevant factors. The 
socioeconomic status has been recognized as a potential source of confounding, as high 
socioeconomic status is associated with MAC and better health outcomes. Finally, our analyses 
were not adjusted for educational attainment, smoking status, and various dietary and physical 
activity factors that may be reflective of socioeconomic status, so residual confounding is 
possible.  
Despite these limitations, our study is based on a unique and very large cohort of non-
Hispanic white individuals with biopsy confirmed NAFLD, who were all prospectively recruited 
in a similar manner, and assessed for their alcohol consumption using standardized 
questionnaires. We additionally confirmed previous associations between MAC and NAFLD 
liver histology severity in terms of effect size and direction, suggesting good internal validity.3, 4  
Few studies have examined the association between the functional ADH1B*2 variant and 
NAFLD histology severity in Caucasians because of its low prevalence, so our study provide 
interesting insights about the relationship between ADH1B alleles, MAC and NAFLD severity in 
this population.  
In conclusion, our results support prior studies that suggest a protective effect of MAC on the 
risk of NASH and fibrosis. Further, ADH1B*2 allele is associated with less severity of NAFLD 
and this protective effect seems to be independent of alcohol consumption; however, among 
moderate drinkers, the risk of NASH is different between each ADH1B alleles. Our results also 
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support a positive dose-dependent relationship between BMI and risk of NASH and fibrosis, 
although this association seems to be significantly modified by ADH1B*2. Our study 
underscores the importance of gene-by-alcohol and/or -BMI associations and the risk of 
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FIGURE LEGENDS 
Figure 1. Flow chart of patient selection. 
Abbreviations: NAFLD, non-alcoholic fatty liver disease. 
Figure 2. Multiplicative effects between ADH1B alleles and MAC, and its impact on liver 
histology severity.  
(A) Predicted probability of definite steatohepatitis based on alcohol consumption (g/day) and
ADH1B alleles. 
(B) Predicted probability of an NAS ≥ 4 based on alcohol consumption (g/day) and ADH1B
alleles. 
Abbreviations: ADH1B, alcohol dehydrogenase class I, beta polypeptide; NAS, NAFLD 
activity score; OR, odd ratio; MAC, moderate alcohol consumption. 
Logistic regression models were used to compute predicted probabilities of histological 
outcomes and margins command to create a visual display of results. Circles on the lines 
represent average adjusted predictions of definite steatohepatitis or an NAS ≥ 4 for each gram of 
alcohol consumed according to ADH1B alleles. All analyses are adjusted by gender, age and 
body mass index (kg/m2). 
* P corresponds with difference of the effect of alcohol consumption (g/day) on definite
steatohepatitis or an NAS ≥4 between ADH1B alleles. 
Figure 3. Association or interaction effects between ADH1B alleles and BMI (kg/m2), and its 
impact on selected histological features of NAFLD.    
(A) Predicted probability of definite NASH based on BMI (kg/m2) and ADH1B alleles.
(B) Association between BMI (kg/m2), ADH1B alleles and categories of steatohepatitis.
(C) Association between BMI (kg/m2), ADH1B alleles and an NAS ≥4.
(D) Association between BMI (kg/m2), ADH1B alleles and fibrosis stages.
Abbreviations: ADH1B, alcohol dehydrogenase class I, beta polypeptide, BMI, body mass
index; NAS, NAFLD activity score.
Logistic regression models were used to compute predicted probabilities of definite NASH and
margins command to create a visual display of results. Circles on the lines represent average
Vilar-Gomez and colleagues (25) 
adjusted predictions of definite NASH for every 2 units of change in BMI (kg/m2) according to 
ADH1B alleles. All analyses are adjusted by gender, age and alcohol consumption. 
* P value corresponds with adjusted logistic regression model.
† P value corresponds with Cochran-Armitage test for trend. 
‡ P value corresponds with Chi-square statistic test. 
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Table 1. Baseline characteristics according to ADH1B*1 or ADH1B*2 alleles among non-Hispanic Whites. 






PNPLA3 rs738409 genotypes, n (%) .829 
 CC  32 (35.6) 345 (32.5) 
 GC 39 (43.3) 489 (46) 
 GG 19 (21.1) 229 (21.5) 
Age, years 51.12 ± 12.31 50.70 ± 11.39 .735 
Gender, n (%) .191 
Male 39 (43) 387 (36) 
Female 51 (57) 676 (64) 
Body mass index (kg/m2) 34.63 ± 6.53 34.89 ± 6.41 .710 
Waist (cm) 110.36 ± 13.77 110.38 ± 14.27 .989 
Type 2 diabetes mellitus, n (%) 29 (32) 379 (36) .513 
Hypertension, n (%) 46 (51) 639 (60) .095 
Lab panel 
Alanine aminotransferase (U/L) 69.03 ± 48.72 70.07 ± 47.12 .841 
Aspartate aminotransferase (U/L) 51.02 ± 33.68 51.38 ± 32.21 .920 
Triglycerides (mg/dl) † 205.28 ± 150.12 184.01 ± 180.25 .068 
Total cholesterol (mg/dl) † 195.44 ± 45.28 192.13 ± 44.23 .573 
HDL cholesterol (mg/dl) † 43.09 ± 10.25 43.36 ± 11.71 .989 
LDL cholesterol (mg/dl) † 116.55 ± 38.33 115.67 ± 37.22 .959 
Fasting glucose (mg/dl) † 103.99 ± 32.27 108.20 ± 37.30 .242 
Insulin (mIU/L) † 19.72 ± 13.67 24.91 ± 25.33 .040 
HOMA-IR † 5.42 ± 5.84 7.21 ± 9.98 .033 
HbA1c (%) † 6.05 ± 1.07 6.18 ± 1.14 .256 
Most recent history of alcohol consumption (2 years preceding the liver biopsy) 
Moderate alcohol consumers, n (%) 35 (39) 398 (37) .785 
Drinks per day (average) 0.78 ± 1.28 0.72 ± 1.22 .641 
Days per month (average) 1.64 ± 3.45 1.55 ± 3.37 .802 
Quantity-frequency index (average) 3.36 ± 7.26 2.99 ± 6.98 .630 
Maximum number of drinks (average) 1.46 ± 2.74 1.27 ± 2.34 .470 
Gram per day (average) 1.68 ± 3.63 1.49 ± 3.49 .630 
Lifetime history of alcohol consumption 
Moderate alcohol consumers, n (%) 46 (51) 507 (48) .533 
Drinks per day (average) 1.26 ± 1.63 1.19 ± 1.60 .667 
Days per month (average) 2.59 ± 3.53 2.58 ± 3.97 .979 
Quantity-frequency index (average) 6.45 ± 9.63 6.24 ± 10.21 .847 
Maximum number of drinks (average) 2.40 ± 3.30 2.21 ± 3.07 .587 
Vilar-Gomez and colleagues (2) 
Gram per day (average) 3.22 ± 4.81 3.12 ± 5.10 .847 
Abbreviations: ADH1B, alcohol dehydrogenase class 1 beta subunit; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; PNPLA3, patatin-like phospholipase domain-containing protein 3.   
Quantity-frequency index: alcohol consumption frequency (number of days drank per month) x quantity (number 
of drinks usually drank on each occasion). Because of the skewed nature of the data, the quantity, frequency, and 
QFI scores were log-transformed [ln (score + 1)] for comparative analysis. 
* T test or Wilcoxon rank-sum test used for continuous variables. Chi-square statistic test used for
categorical variables. Mantel-Haenszel trend test used for binary categorical variables with three or more
groups.
† Log-transformed variables.
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Table 2. Influence of alcohol consumption or ADH1B alleles on liver histology severity among non-Hispanic Whites. Results based on univariate and 
multivariable analysis.     
 
Histopathological report 

























Steatosis, n (%)   .074 1.24 (0.99-1.56) .062   .568 0.93 (0.63-1.38) .724 
    <5% 6 (1.4) 15 (2.1)    1 (1.1) 20 (1.9)    
   5-33% 142 (32.8) 278 (38.6)    34 (37.8) 386 (36.3)    
   33-66%  168 (38.8) 245 (34)    36 (40) 377 (35.5)    
   >66% 117 (27) 182 (25.3)    19 (21.1) 280 (26.3)    
Lobular inflammation, n (%)   .317 0.98 (0.77-1.25) .898   .033 0.63 (0.41-0.98) .044 
    No foci 2 (0.5) 0 (0)    1 (1.1) 1 (0.1)    
    <2 foci/200x 233 (53.8) 373 (51.8)    56 (62.2) 550 (51.7)    
    2-4 foci/200x 154 (35.6) 265 (36.8)    26 (28.9) 393 (37)    
    >4 foci/200x 44 (10.2) 82 (11.4)    7 (7.8) 119 (11.2)    
Ballooning, n (%)   <.001 0.82 (0.65-1.03) .095   .002 0.53 (0.35-0.80) .003 
    None 168 (38.8) 215 (29.8)    45 (50) 338 (31.8)    
    Few 123 (28.4) 197 (27.4)    19 (21.1) 301 (28.3)    
    Many 142 (32.8) 308 (42.8)    26 (28.9) 424 (39.9)    
Portal inflammation, n (%)   .014 0.85 (0.66-1.10) .227   .935 1.04 (0.67-1.62) .850 
    None 56 (12.9) 70 (9.7)    8 (8.9) 118 (11.1)    
    Mild 284 (65.6) 456 (63.3)    61 (67.8) 679 (63.9)    
    > Mild 93 (21.5) 194 (27)    21 (23.3) 266 (25)    
Fibrosis stages, n (%)   <.001 0.68 (0.55-0.85) .001   .085 0.69 (0.47-0.99) .050 
   0 120 (27.7) 138 (19.2)    28 (31.1) 230 (21.6)    
   1 133 (30.7) 180 (25)    21 (23.3) 292 (27.5)    
   2 74 (17.1) 164 (22.8)    19 (21.1) 219 (20.6)    
   3 73 (16.9) 154 (21.4)    16 (17.8) 211 (19.8)    
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   4 33 (7.6) 84 (11.6) 6 (6.7) 111 (10.4) 
Mallory-Denk bodies, n (%) .001 0.82 (0.62-1.08) .155 .061 0.63 (0.37-1.05) .081 
 Rare 314 (73) 454 (63) 68 (76) 700 (66) 
 Many 119 (27) 266 (37) 22 (24) 363 (34) 
Steatohepatitis, n (%) <.001 0.73 (0.57-0.94) .013 .001 0.52 (0.34-0.78) .002 
 No steatohepatitis 105 (24.2) 132 (18.3) 30 (33.3) 207 (19.5) 
 Borderline steatohepatitis 102 (23.6) 125 (17.4) 20 (22.2) 207 (19.5) 
 Definite steatohepatitis 226 (52.2) 463 (64.3) 40 (44.4) 649 (61.1) 
Definite steatohepatitis, n (%) 226 (52.2) 463 (64.3) <.001 0.70 (0.54-0.91) .008 40 (44.4) 649 (61.1) .001 0.50 (0.31-0.79) .003 
NAS ≥4, n (%) 236 (54) 454 (63) .004 0.77 (0.60-0.99) .048 39 (43) 651 (61) .001 0.48 (0.30-0.75) .001 
Advanced fibrosis (F≥3), n (%) 106 (25) 238 (33) .002 0.77 (0.58-1.02) .073 22 (24) 322 (30) .244 0.74 (0.44-1.26) .274 
Abbreviations: ADH1B, alcohol dehydrogenase class 1 beta subunit; OR, odd ratio; CI, confidence interval; NAS, NAFLD activity score. 
* Chi-square statistic test used for binary and Cochran-Armitage trend test used for ordered alternatives.
† Covariate-adjusted ordered or binary logistic regression. Adjustment by age, gender, BMI (kg/m2), type 2 diabetes mellitus and PNPLA3 rs738409. Both
the most recent history of alcohol consumption and ADH1B alleles were included in the same multivariable adjusted log models. 
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Table 3. Association between different cutoffs of alcohol consumption and baseline characteristics among non-Hispanic Whites.  
 Most recent history of alcohol consumption (g/day) 









ADH1B, n (%)     .512 
  ADH1B*1  665 (92) 325 (93) 51 (85) 22 (96)  
  ADH1B*2  55 (8) 25 (7) 9 (15) 1 (4)  
PNPLA3 rs738409 genotypes, n (%)     .842 
  GG 146 (20.3) 87 (24.8) 10 (16.7) 5 (22.7)  
  CG 340 (47.2) 147 (41.9) 33 (55) 8 (36.4)  
  CC 234 (32.5) 117 (33.3) 17 (28.3) 9 (40.9)  
Body mass index (kg/m2) 35.29 ± 6.55 34.44 ± 6.27 32.64 ± 5.03 34.28 ± 6.20 .007 
Type 2 diabetes mellitus, n (%)  284 (39) 105 (30) 16 (27) 3 (13) <.001 
Hypertension, n (%) 455 (63) 184 (53) 30 (50) 15 (68) .003 
Lab panel      
Alanine aminotransferase (U/L) 68.06 ± 45.88 72.83 ± 50.80 71.93 ± 42.74 82.45 ± 41.48 .251 
Aapartate aminotransferase (U/L) 52.18 ± 34.11 50.05 ± 29.51 49.93 ± 29.93 48.95 ± 17.93 .735 
Triglycerides (mg/dl) † 187.22 ± 175.51 185.73 ± 189.36 152.10 ± 77.90 224.77 ± 258.14 .192 
Total cholesterol (mg/dl) † 193.64 ± 46.00 188.80 ± 40.89 195.38 ± 44.94 200.05 ± 36.22 .366 
HDL cholesterol (mg/dl) † 43.24 ± 11.43 43.03 ± 11.62 45.78 ± 11.93 44.86 ± 15.06 .359 
LDL cholesterol (mg/dl) † 116.68 ± 38.11 112.65 ± 35.46 120.32 ± 38.66 122.05 ± 33.34 .385 
Fasting glucose (mg/dl) † 108.33 ± 38.54 107.65 ± 34.68 106.07 ± 34.99 101.32 ± 21.34 .872 
HOMA-IR † 7.19 ± 9.48 7.19 ± 10.37 4.82 ± 4.07 4.64 ± 3.58 .016 
HbA1c (%) † 6.22 ± 1.17 6.14 ± 1.09 5.93 ± 0.97 5.98 ± 1.13 .189 
Histopathological reports      
Steatosis, n (%)     .112 
    <5% 15 (2.1) 5 (1.4) 1 (1.7) 0 (0)  
   5-33% 278 (38.6) 114 (32.5) 21 (35) 7 (31.8)  
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33-66% 245 (34) 138 (39.3) 20 (33.3) 10 (45.5) 
>66% 182 (25.3) 94 (26.8) 18 (30) 5 (22.7) 
Lobular inflammation, n (%) .433 
 No foci 0 (0) 1 (0.3) 1 (1.7) 0 (0) 
 <2 foci/200x 373 (51.8) 189 (53.8) 35 (58.3) 9 (41) 
2-4 foci/200x 265 (36.8) 124 (35.4) 18 (30) 12 (54.5) 
>4 foci/200x 82 (11.4) 37 (10.5) 6 (10) 1 (4.5) 
Ballooning, n (%) <.001 
 None 215 (29.9) 130 (37) 29 (48.3) 9 (40.9) 
 Few 197 (27.4) 98 (27.9) 15 (25) 10 (45.5) 
 Many 308 (42.7) 123 (35.1) 16 (26.7) 3 (13.6) 
Portal inflammation, n (%) <.001 
 None 70 (9.8) 39 (11.1) 11 (18.3) 6 (27.3) 
 Mild 456 (63.3) 229 (65.2) 42 (70) 13 (59.1) 
> Mild 194 (26.9) 83 (23.6) 7 (11.7) 3 (13.6) 
Fibrosis stages, n (%) <.001 
 0 138 (19.1) 93 (26.5) 23 (38.3) 4 (18.2) 
 1 180 (25) 106 (30.2) 19 (31.7) 8 (36.4) 
 2 164 (22.8) 59 (16.8) 11 (18.3) 4 (18.2) 
 3 154 (21.4) 63 (17.9) 4 (6.7) 6 (27.3) 
 4 84 (11.7) 30 (8.6) 3 (5) 0 (0) 
Mallory-Denk bodies, n (%) <.001 
 Rare 454 (63) 249 (71) 45 (75) 20 (91) 
 Many 266 (37) 102 (29) 15 (25) 2 (9) 
Category of steatohepatitis, n (%) <.001 
 No steatohepatitis 132 (18.3) 80 (22.8) 22 (36.7) 3 (13.6) 
 Borderline steatohepatitis 125 (17.4) 82 (23.4) 12 (20) 8 (36.4) 
 Definite steatohepatitis 463 (64.3) 189 (53.8) 26 (43.3) 11 (50) 
Definite steatohepatitis 463 (64) 189 (54) 26 (43) 11 (50) <.001 
  Vilar-Gomez and colleagues (7) 
 
NAS ≥4 454 (63) 197 (56) 27 (45) 12 (54) .003 
Advanced fibrosis (F≥3), n (%) 238 (33) 93 (27) 7 (12) 6 (27) .001 
Abbreviations: ADH1B, alcohol dehydrogenase class 1 beta subunit; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
PNPLA3, patatin-like phospholipase domain-containing protein 3; NAS, NAFLD activity score.  
* Cochran-Armitage trend test used for ordered alternatives, Mantel-Haenszel trend test used for binary categorical variables with 3 or more 
groups, and one-way ANOVA used for continuous variables with Bonferroni correction for multiple comparisons.  
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Table 4. Association between ADH1B alleles and liver histology phenotypes among non-Hispanic whites. Sensitivity 
analysis based on the most recent history of alcohol consumption. 

















Steatosis, n (%) .950 .380 
 <5% 1 (1.8) 14 (2.1) 0 (0) 6 (1.5) 
5-33% 21 (38.2) 257 (38.6) 13 (37.1) 129 (32.4) 
33-66% 20 (36.4) 225 (33.8) 16 (45.8) 152 (38.2) 
>66% 13 (23.6) 169 (25.4) 6 (17.1) 111 (27.9) 
Lobular inflammation, n (%) .016 .716 
 No foci 0 (0) 0 (0) 1 (2.9) 1 (0.3) 
 <2 foci/200x 36 (65.5) 337 (50.7) 20 (57.1) 213 (53.5) 
2-4 foci/200x 17 (30.9) 248 (37.3) 9 (25.7) 145 (36.4) 
>4 foci/200x 2 (3.6) 80 (12) 5 (14.3) 39 (9.8) 
Ballooning, n (%) .177 .001 
 None 22 (40) 193 (29) 23 (65.7) 145 (36.4) 
 Few 12 (21.8) 185 (27.8) 7 (20) 116 (29.1) 
 Many 21 (38.2) 287 (43.2) 5 (14.3) 137 (34.4) 
Portal inflammation, n (%) .722 .542 
 None 4 (7.3) 66 (9.9) 4 (11.4) 52 (13.1) 
 Mild 39 (70.9) 417 (62.7) 22 (62.9) 262 (65.8) 
> Mild 12 (21.8) 182 (27.4) 9 (25.7) 84 (21.1) 
Fibrosis stages, n (%) .288 .159 
 0 13 (23.6) 125 (18.8) 15 (42.9) 105 (26.4) 
 1 12 (21.8) 168 (25.3) 9 (25.7) 124 (31.2) 
 2 16 (29.1) 148 (22.3) 3 (8.6) 71 (17.8) 
 3 10 (18.2) 144 (21.7) 6 (17.1) 67 (16.8) 
 4 4 (7.3) 80 (12) 2 (5.7) 31 (7.8) 
Mallory-Denk bodies, n (%) .500 .027 
 Rare 37 (67) 417 (63) 31 (89) 283 (71) 
 Many 18 (33) 248 (37) 4 (11) 115 (29) 
Steatohepatitis, n (%) .138 <.001 
 No steatohepatitis 14 (25.5) 118 (17.7) 16 (45.7) 89 (22.4) 
 Borderline steatohepatitis 10 (18.2) 115 (17.3) 10 (28.6) 92 (23.1) 
 Definite steatohepatitis 31 (56.4) 432 (65) 9 (25.7) 217 (54.5) 
Definite steatohepatitis, n (%) 31 (56) 432 (65) .201 9 (26) 217 (55) .001 
NAS ≥4, n (%) 29 (53) 425 (64) .099 10 (29) 226 (57) .001 
Advanced fibrosis (F≥3), n (%) 14 (25) 224 (34) .212 8 (23) 98 (25) .816 
Vilar-Gomez and colleagues (9) 
Abbreviations: ADH1B, alcohol dehydrogenase class 1 beta subunit; NAS, NAFLD activity score. 




What you need to know: 
Background and Context: The ADH1B*2 allele of the alcohol dehydrogenase 1B gene is 
associated with higher alcohol metabolism and might affect the relationship between moderate 
alcohol consumption and severity of NAFLD. 
New Findings: In an analysis of data from the nonalcoholic steatohepatitis (NASH) clinical 
research network, from 1153 patients with NAFLD, the authors found that ADH1B*2 reduces the 
risk of NASH and fibrosis in adults with NAFLD regardless of alcohol consumption status.  
Limitations: This was an analysis of mostly white patients; larger studies of more diverse groups 
are needed. Studies are also needed to determine them mechanisms by which the ADH1B*2 
allele might reduce risk of severe NAFLD. 
Impact: These observations might shed further light on the pathogenesis of NASH and facilitate 
the development of new therapies.  
